Agreement - October 13, 2014
Enzymatica expands in Denmark
Enzymatica has signed agreements with the pharmacy chain Pharma+ and the wellness chain Matas in Denmark to sell ColdZyme. From November this year, ColdZyme will be available on the Danish market, and thus in all of Scandinavia. “According to plan, we are expanding to our neighboring countries using our own sales organization, building a platform of […]
Uncategorized - October 10, 2014
Smartphone app in diabetes treatment reduces blood glucose levels
A type 2 diabetes clinical study from Karolinska Institutet showed lower blood glucose when using remote diabetes care system with patient app. The main finding reported by Professor Kerstin Brismar from Karolinska Institutet showed that by using the Triabetes smartphone app and TriabetesClinic online decision support service in Type 2 diabetes treatment long-term blood glucose […]
Clinical Trials - October 10, 2014
Promising results from Medivir’s pain study
Medivir announces that promising data from its cathepsin S inhibitor drug development program for neuropathic pain will be presented at The 15th World Congress on Pain. The data to be presented support the development of a potent oral cathepsin S inhibitor such as MIV-247 as a new treatment for neuropathic pain. MIV-247 is a potent and […]
Clinical Trials - October 10, 2014
AstraZeneca presents positive results from asthma study
Positive safety and efficacy data from a Phase IIb study evaluating benralizumab has been published, announces AstraZeneca. The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory […]
Uncategorized - October 9, 2014
Digital health programme to launch in Finland
Tekes, the Finnish Funding Agency for Innovation, is investing in the country’s digital health sector and launches programmes to utilise digital technology. Tekes is launching a major programme to boost Finland’s digital health ecosystem, with funding available for pilot and development projects. The goal of the Health from Bits (Terveyttä biteistä) programme is to raise Finland to […]
Agreement - October 9, 2014
Dilafor signs agreement with Opocrin
Swedish Dilafor AB and Italian Opocrin S.p.A. have entered into a commercial supply and partnership agreement. In the agreement, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for Dilafor’s candidate drug tafoxiparin for the European, US, CIS and Japanese markets. Opocrin will also supply manufacturing services during […]
